Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | JNJ-64041757 |
| Trade Name | |
| Synonyms | ADU-214|JNJ-757|Pemlimogene merolisbac |
| Drug Descriptions |
JNJ-64041757 (pemlimogene merolisbac) is a immunotherapy based on live attenuated Listeria monocytogenes, which may enhance immune response against mesothelin-expressing tumor cells (J Thoracic Oncol, Vol 12, Issue 11, S2151). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C124843 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| JNJ-64041757 | JNJ-64041757 | 0 | 0 |
| JNJ-64041757 + Nivolumab | JNJ-64041757 Nivolumab | 0 | 1 |